ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ekberg-Jansson, A
Right arrow Articles by Larsson, S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ekberg-Jansson, A
Right arrow Articles by Larsson, S
Eur Respir J 1999; 13: 829-834
Copyright © ERS Journals Ltd 1999


Clinical Trial

N-isobutyrylcysteine, a donor of systemic thiols, does not reduce the exacerbation rate in chronic bronchitis

A Ekberg-Jansson, M Larson, W MacNee, A Tunek, L Wahlgren, EF Wouters, and S Larsson

N-isobutyrylcysteine (NIC), a new thiol compound that is not rapidly hydrolysed to give higher levels of free thiols in the body than N-acetylcysteine (NAC), was used to test if the effect of NAC on exacerbations in chronic bronchitis was an effect of the unhydrolysed thiol compound. Smokers or exsmokers with chronic bronchitis forced expiratory volume in one second (FEV1) >40% and reversibility < or = 10% predicted were treated with oral NIC 300 mg b.i.d. or placebo for 24 weeks. Steroids, NAC, antibiotics, and nonsteroid anti-inflammatory drugs use were restricted. Exacerbations were recorded by a respiratory symptom diary card and the time to onset of the first exacerbation after the start of treatment was measured using life-table analysis. Spirometry was performed at each visit. Six hundred and thirty-seven patients were randomized to treatment with NIC (n=316) or placebo (n=321). NIC did not prolong the time to first exacerbation (life-table analysis, p=0.59) and no increase in FEV1 or forced vital capacity was observed. Altered taste perception, taste loss and anosmia occurred more often in the NIC group (p<0.001). In conclusion, N-isobutyrylcysteine, a N-acetylcysteine-like drug with a greater bioavailability has, contrary to N-acetylcysteine, no effect on exacerbations in chronic bronchitis. This suggests that the effect of N-acetylcysteine on exacerbations in chronic bronchitis is not due to the relatively low free thiol levels (other than glutathione) produced by N-acetylcysteine therapy.


This article has been cited by other articles:


Home page
Ther Adv Respir DisHome page
I. Rahman
Review: Antioxidant therapeutic advances in COPD
Therapeutic Advances in Respiratory Disease, December 1, 2008; 2(6): 351 - 374.
[Abstract] [PDF]


Home page
Eur Respir JHome page
I. Rahman and I. M. Adcock
Oxidative stress and redox regulation of lung inflammation in COPD.
Eur. Respir. J., July 1, 2006; 28(1): 219 - 242.
[Abstract] [Full Text] [PDF]


Home page
ERRHome page
W. MacNee
Treatment of stable COPD: antioxidants
Eur. Respir. Rev., September 1, 2005; 14(94): 12 - 22.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
A. Ekberg-Jansson, S. Larsson, and C.-G. Lofdahl
Preventing exacerbations of chronic bronchitis and COPD
BMJ, May 26, 2001; 322(7297): 1259 - 1261.
[Full Text] [PDF]


Home page
BMJHome page
P. J Poole and P. N Black

BMJ, May 26, 2001; 322(7297): 1271 - 1271.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the European Respiratory Society.